405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019

Background

The EMOO in Asia Study established a clinical annotated population-based registry of lung cancer in a collaboration between ESMO, the International Agency for Research on Cancer, and partner institutions in Indonesia, Malaysia and Singapore and Thailand.

Methods

A retrospective study was conducted based on incident lung cancer cases diagnosed between 2017 – 2019 in Lampang (Thailand), Penang (Malaysia), and Yogyakarta (Indonesia) and a clinical case series obtained from the National Cancer Center in Singapore. Tumour and clinical information were abstracted by chart review according to a predefined study protocol.

Results

3,413 lung cancer cases registed in the database. The median age at diagnosis was 62 years, 62% of patients were male, 38% female. Smoking status was documented in 3,007 patients; with 24%, 31% and 45% being current smokers, ever smokers and never smokers, respectively. Diagnosed was based on pathological findings in 87% of cases (histology 73% and cytology 27%) and on clinical and/or /imaging findings in 13%. SCLC was diagnosed in 6% and NSCLC in 92%, the majority (82%) being non-squamous histology. Data on stage distribution from SCLC was available for 153 patients and included 26% with stages I-III and 74% with stage IV. The respective actuarial 1-year survival was 63% and 32%. NSCLC was diagnosed in 92% of the cases. Data on stage distribution from patients with NSCLC was available for 2,534 patients and included stage I/II in 17%, stage III in 14% and stage IV in 69%. The respective actuarial 1-year survival by stage was 93%, 64% and 47%. The survival by stage varied between the regions ranging from 57-96% for stage I and II, 40-96% for stage III and 29-67% for stage IV. Treatment patterns according to regions will be further detailed.

Conclusions

Analysis of data from a clinically annotated registry for lung cancer from four settings in South-East Asia demonstrated integrating clinical data within population-based cancer registries was feasible. The proportion of cases with a pathologic diagnosis can be improved and the 1-year survival according to stage varied between regions.

Clinical trial identification

Editorial acknowledgement

Disclosure

R.A. Soo: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Astra-Zeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Lily; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Other, Conference sponsorship: Taiho; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Yuhan; Financial Interests, Institutional, Research Grant: Astra-Zeneca; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim. R. Kanesvaran: Financial Interests, Institutional, Invited Speaker: Astellas; Financial Interests, Institutional, Invited Speaker: Johnson and Johnson; Financial Interests, Institutional, Advisory Board: Johnson and Johnson; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Invited Speaker: Ipsen; Financial Interests, Institutional, Advisory Board: Ipsen; Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Invited Speaker: Amgen; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Invited Speaker: BMS; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Invited Speaker: MSD; Financial Interests, Institutional, Invited Speaker: Novartis; Financial Interests, Institutional, Advisory Board: Bayer; Financial Interests, Institutional, Advisory Board: AstraZaneca; Financial Interests, Institutional, Invited Speaker: AstraZaneca; Financial Interests, Institutional, Advisory Board: Ferring; Financial Interests, Institutional, Invited Speaker: Sanofi; Financial Interests, Institutional, Research Grant: Sanofi; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Institutional, Research Grant: Johnson and Johnson; Non-Financial Interests, Personal, Leadership Role, Past President: Singapore Society of Oncology; Non-Financial Interests, Personal, Leadership Role, President: SIOG; Non-Financial Interests, Personal, Leadership Role, Vice Chairman: Singapore Cancer Society; Non-Financial Interests, Personal, Leadership Role, Medical Advisory Board Member: International Kidney Cancer Coalition. N. Prasongsook: Financial Interests, Personal, Advisory Board: Roche (Thailand); Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer. S. Peters: Financial Interests, Institutional, Advisory Board: Vaccibody; Financial Interests, Institutional, Advisory Board: Takeda; Financial Interests, Institutional, Invited Speaker: Takeda; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Advisory Board: Sanofi; Financial Interests, Institutional, Invited Speaker: Sanofi; Financial Interests, Institutional, Invited Speaker: Roche/Genentech; Financial Interests, Institutional, Advisory Board: Roche/Genentech; Financial Interests, Institutional, Advisory Board: Regeneron; Financial Interests, Institutional, Invited Speaker: RTP; Financial Interests, Institutional, Advisory Board: Phosplatin Therapeutics; Financial Interests, Institutional, Advisory Board: PharmaMar; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Invited Speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: PRIME; Financial Interests, Institutional, Invited Speaker: PER; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Invited Speaker: Novartis; Financial Interests, Institutional, Advisory Board: Mirati; Financial Interests, Institutional, Advisory Board: Merck Serono; Financial Interests, Institutional, Invited Speaker: Medscape; Financial Interests, Institutional, Invited Speaker: MSD; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Advisory Board: Incyte; Financial Interests, Institutional, Invited Speaker: Imedex; Financial Interests, Institutional, Advisory Board: Illumina; Financial Interests, Institutional, Invited Speaker: Illumina; Financial Interests, Institutional, Advisory Board: IQVIA; Financial Interests, Institutional, Advisory Board: GlaxoSmithKline; Financial Interests, Institutional, Advisory Board: Gilhead; Financial Interests, Institutional, Advisory Board: Genzyme; Financial Interests, Institutional, Advisory Board: Foundation Medicine; Financial Interests, Institutional, Invited Speaker: Fishawack; Financial Interests, Institutional, Advisory Board: F-Star; Financial Interests, Personal, Other, Associate Editor Annals of Oncology: Elsevier; Financial Interests, Institutional, Advisory Board: Eli Lilly; Financial Interests, Institutional, Invited Speaker: Eli Lilly; Financial Interests, Institutional, Invited Speaker: Ecancer; Financial Interests, Institutional, Advisory Board: Debiopharm; Financial Interests, Institutional, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Advisory Board: Boehringer Ingelheim; Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim; Financial Interests, Institutional, Advisory Board: Blueprint Medicines; Financial Interests, Institutional, Advisory Board: Biocartis; Financial Interests, Institutional, Advisory Board: Bio Invent; Financial Interests, Institutional, Advisory Board: BeiGene; Financial Interests, Institutional, Advisory Board: Bayer; Financial Interests, Institutional, Invited Speaker: BMS; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: Arcus; Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Advisory Board: AbbVie; Financial Interests, Institutional, Advisory Board: iTheos; Financial Interests, Institutional, Advisory Board: Novocure; Financial Interests, Institutional, Invited Speaker: OncologyEducation; Financial Interests, Institutional, Invited Speaker: RMEI; Financial Interests, Institutional, Invited Speaker: Mirati; Financial Interests, Institutional, Invited Speaker, MERMAID-1: AstraZeneca; Financial Interests, Institutional, Invited Speaker, MERMAID-2, POSEIDON, MYSTIC: AstraZeneca; Financial Interests, Institutional, Invited Speaker, Clinical Trial Steering committee CheckMate 743, CheckMate 73L, CheckMate 331 and 451: BMS; Financial Interests, Institutional, Invited Speaker, RELATIVITY 095: BMS; Financial Interests, Institutional, Invited Speaker, BGB-A317-A1217-301/AdvanTIG-301: Beigene; Financial Interests, Institutional, Invited Speaker, Clinical Trial Chair ZEAL-1: GSK; Financial Interests, Institutional, Invited Speaker, Clinical Trial steering Committee PEARLS, MK-7684A: MSD; Financial Interests, Institutional, Invited Speaker, Clinical Trial Steering Committee SAPPHIRE: Mirati; Financial Interests, Institutional, Invited Speaker, LAGOON: Pharma Mar; Financial Interests, Institutional, Invited Speaker, phase 1/2 trials: Phosplatin Therapeutics; Financial Interests, Institutional, Invited Speaker, Clinical Trial Chair Skyscraper-01; chair ALEX; steering committee BFAST; steering committee BEAT-Meso; steering committee ImPower-030, IMforte: Roche/Genentech; Financial Interests, Institutional, Invited Speaker, Phase 2 Inupadenant with chemo: iTeos; Non-Financial Interests, Personal, Officer, ESMO President 2020-2022: ESMO; Non-Financial Interests, Personal, Officer, Council Member & Scientific Committee Chair: ETOP/IBCSG Partners; Non-Financial Interests, Personal, Officer, Vice-President Lung Group: SAKK; Non-Financial Interests, Personal, Other, Involved in Swiss politics: Swiss Political Activities; Non-Financial Interests, Personal, Officer, President and Council Member: Ballet Béjart Lausanne Foundation; Non-Financial Interests, Personal, Principal Investigator, Involved in academic trials: ETOP / EORTC / SAKK; Non-Financial Interests, Personal, Member: Association of Swiss Physicians FMH (CH); Non-Financial Interests, Personal, Leadership Role, ESMO President: ESMO; Non-Financial Interests, Personal, Member: ASCO; Non-Financial Interests, Personal, Member: AACR; Non-Financial Interests, Personal, Member: IASLC; Non-Financial Interests, Personal, Member, Vice-President Lung Group: SAKK; Non-Financial Interests, Personal, Leadership Role, Vice -President: SAMO; Non-Financial Interests, Personal, Member, Association of Swiss interns and residents: ASMAC/VSAO. R. Stahel: Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: AZ; Financial Interests, Personal, Invited Speaker: Blueprint; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: BI; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: AZ; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: BI; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Institutional, Other: AZ; Financial Interests, Institutional, Other: BMS; Financial Interests, Institutional, Other: Daiichi Sankyo; Financial Interests, Institutional, Other: Celgene; Financial Interests, Institutional, Other: Ipsen; Financial Interests, Institutional, Other: Janssen; Financial Interests, Institutional, Other: Mirati; Financial Interests, Institutional, Other: MSD; Financial Interests, Institutional, Other: Novartis; Financial Interests, Institutional, Other: Pfizer; Financial Interests, Institutional, Other: Pierre Fabre; Financial Interests, Institutional, Other: Roche. All other authors have declared no conflicts of interest.